Atea Pharmaceuticals to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023

BOSTON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced two upcoming poster presentations at The Liver Meeting 2023, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), which will take place from November 10-14, 2023 in Boston, MA.

"We are very pleased to share with the scientific and clinical community supportive data for bemnifosbuvir and ruzasvir, highlighting the potential to use these two compounds together as a novel treatment for hepatitis C virus (HCV)," said Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals. "We are encouraged by the highly potent, pan-genotypic antiviral activity of these compounds, along with the favorable drug-drug interaction and safety profile observed to-date, which supports their use in combination. Despite treatment options for HCV, there remains a large, underserved HCV patient population that continues to grow dramatically due to the opioid crisis, injection drug use and HCV reinfection."

Details for the presentations are as follows:

Poster Number: 1861-A
Title: Bemnifosbuvir and Ruzasvir are Potent HCV DAAs with Favorable Antiviral Profiles Against Major HCV NS5A and NS5B RAVs Supporting Use in Combination 
Date and Time: Friday, November 10, 1:00 PM – 2:00 pm
Location: Hall A

Poster Number: 1879-A
Title: Lack of Pharmacokinetic Drug-Drug Interaction Between Bemnifosbuvir and Ruzasvir in Healthy Participants 
Date and Time: Friday, November 10, 1:00 PM – 2:00 PM
Location: Hall A

About Bemnifosbuvir and Ruzasvir for Hepatitis C Virus (HCV)

Atea is currently conducting a Phase 2 open-label study evaluating bemnifosbuvir in combination with ruzasvir (RZR) in treatment-naïve HCV-infected patients, either without cirrhosis and or with compensated cirrhosis. This study aims to assess the safety and efficacy of eight weeks of treatment with the pan-genotypic combination, consisting of once-daily bemnifosbuvir 550 mg and RZR 180 mg. Approximately 280 treatment-naïve HCV-infected patients are anticipated to be enrolled across all genotypes, including a 60 patient lead-in cohort.